Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Challenges Ongoing Loss Narrative [Yahoo! Finance]
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: Yahoo! Finance
five years and no positive EPS expected in the next three years. Despite the unprofitable streak, revenue is forecast to surge by 28.79% a year, far exceeding the US market's 10.5% average. For investors, the strong top-line growth outlook stands in sharp contrast to persistent losses and a relatively high price-to-sales ratio. This frames a complex but compelling earnings picture. See our full analysis for Foghorn Therapeutics. The next section will put these headline numbers side by side with the core narratives followed by investors. This reveals where market stories align with the hard data and where surprises might lurk. Curious how numbers become stories that shape markets? Explore Community Narratives NasdaqGM:FHTX Earnings & Revenue History as at Nov 2025 Losses Mount as Revenue Acceleration Outpaces Peers Foghorn's losses have been worsening at a 1.4% annual pace over five years, and the company is projected to stay unprofitable for at least three more years. Wh
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FHTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- 4D Molecular Therapeutics taps Kristian Humer as CFO [Seeking Alpha]Seeking Alpha
- 4DMT Appoints Kristian Humer as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 11/5/25 - Beat
FHTX
Sec Filings
- 12/4/25 - Form 8-K
- 11/17/25 - Form 4
- 11/7/25 - Form 8-K
- FHTX's page on the SEC website